Medtronic (NYSE:MDT) CEO Geoffrey Martha Sells 50,000 Shares of Company Stock

Key Points

• Medtronic CEO Geoffrey Martha sold 50,000 shares at an average price of $95, generating $4.75 million. The transaction was conducted under a pre-arranged Rule 10b5-1 plan, and Martha retained 277,866 shares.
• Medtronic recently exceeded quarterly expectations, reporting $1.45 in EPS and $9.76 billion in revenue, with revenue up 13.7% year over year. The company also pays a quarterly dividend of $0.72 per share, equivalent to a 3.0% annual yield.
• MDT shares were trading near $94.79, while analysts maintained a generally positive but cautious outlook, with a consensus “Moderate Buy” rating and an average price target of $102.88.

Medtronic PLC (NYSE:MDT - Get Free Report) CEO Geoffrey Martha sold 50,000 shares of the business's stock in a transaction on Thursday, October 15th. The stock was sold at an average price of $95.00, for a total transaction of $4,750,000.00. Following the sale, the chief executive officer directly owned 277,866 shares in the company, valued at approximately $26,397,270. The trade was a 15.25% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Medtronic Price Performance

Shares of NYSE MDT traded down $0.66 during mid-day trading on Friday, hitting $94.79. 30,274,266 shares of the stock traded hands, compared to its average volume of 11,408,682. The company has a debt-to-equity ratio of 0.50, a current ratio of 2.07 and a quick ratio of 1.54. Medtronic PLC has a twelve month low of $73.31 and a twelve month high of $106.33. The company has a market cap of $121.25 billion, a PE ratio of 23.35, a price-to-earnings-growth ratio of 2.15 and a beta of 0.55. The firm has a 50 day simple moving average of $90.87 and a two-hundred day simple moving average of $84.95.

Medtronic (NYSE:MDT - Get Free Report) last released its quarterly earnings data on Tuesday, September 1st. The medical technology company reported $1.45 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.39 by $0.06. Medtronic had a return on equity of 14.78% and a net margin of 13.93%. The company had revenue of $9.76 billion during the quarter, compared to the consensus estimate of $9.55 billion. During the same quarter in the prior year, the firm posted $1.26 earnings per share. The firm's revenue was up 13.7% compared to the same quarter last year. Medtronic has set its Q2 2027 guidance at 1.320-1.340 EPS and its FY 2027 guidance at 5.940-6.000 EPS. As a group, equities research analysts forecast that Medtronic PLC will post 5.98 EPS for the current fiscal year.

Medtronic Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Friday, October 16th. Stockholders of record on Friday, September 25th will be issued a dividend of $0.72 per share. This represents a $2.88 dividend on an annualized basis and a dividend yield of 3.0%. The ex-dividend date is Friday, September 25th. Medtronic's payout ratio is 70.94%.

Medtronic News Roundup

Here are the key news stories impacting Medtronic this week:

• Positive Sentiment: Medtronic’s Stealth AXiS surgical system and Corsano multi-parameter wearable were named to TIME’s 2026 Best Inventions list. The recognition supports the company’s innovation strategy and could improve visibility for its surgical and monitoring businesses. Medtronic Named to TIME Best Inventions of 2026
• Positive Sentiment: Medtronic continues expanding in cardiac ablation, robotics, hypertension and digital surgery. Recent sales and profit growth, along with a raised fiscal outlook, provide support for the longer-term investment case. Is Medtronic Stock a Buy Now That Sales Growth Has Picked Up?
• Neutral Sentiment: Medtronic completed the separation of MiniMed, exchanging its remaining shares and leaving the diabetes-technology company fully independent. The transaction simplifies MDT’s portfolio and may allow greater focus on higher-growth medical-device businesses, but it also removes direct ownership of MiniMed and changes the company’s revenue mix. Medtronic Completes Separation of MiniMed Group
• Negative Sentiment: Analyst sentiment remains cautious: Piper Sandler assigned a Hold rating, while Barclays began coverage at Equal Weight. These ratings suggest limited near-term upside after MDT’s recent advance. Medtronic Receives a Hold from Piper Sandler
• Negative Sentiment: Tariffs, inflation and unfavorable currency movements could pressure Medtronic’s margins. ETFs also reportedly sold $222.5 million of MDT shares on October 13, adding a potential short-term technical headwind. Is it Apt to Retain Medtronic Stock in Your Portfolio Now?

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of MDT. Monetary Solutions Ltd bought a new position in Medtronic during the fourth quarter worth $27,000. Activest Wealth Management lifted its holdings in Medtronic by 470.9% in the third quarter. Activest Wealth Management now owns 314 shares of the medical technology company's stock valued at $27,000 after buying an additional 259 shares during the period. IAG Wealth Partners LLC bought a new stake in Medtronic during the second quarter valued at $30,000. Pin Oak Investment Advisors Inc. bought a new stake in Medtronic during the second quarter valued at $32,000. Finally, Global Assets Advisory LLC bought a new stake in Medtronic during the first quarter valued at $36,000. Institutional investors and hedge funds own 82.06% of the company's stock.

Analyst Ratings Changes

A number of analysts recently weighed in on MDT shares. Wells Fargo & Company increased their price objective on Medtronic from $102.00 to $104.00 and gave the company an "overweight" rating in a report on Wednesday, September 2nd. Mizuho set a $115.00 target price on Medtronic in a report on Wednesday, September 2nd. BTIG Research cut their target price on Medtronic from $100.00 to $99.00 and set a "buy" rating on the stock in a report on Monday. Stifel Nicolaus upped their price target on Medtronic from $80.00 to $95.00 and gave the company a "hold" rating in a research report on Wednesday, September 2nd. Finally, Royal Bank Of Canada reissued an "outperform" rating and issued a $118.00 price target on shares of Medtronic in a research note on Wednesday, September 2nd. Seventeen equities research analysts have rated the stock with a Buy rating, ten have assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, Medtronic currently has a consensus rating of "Moderate Buy" and a consensus target price of $102.88.

Medtronic Company Profile

Medtronic plc is a global medical technology company that develops and manufactures devices, therapies and healthcare solutions for treating chronic and acute conditions. Its products are used in areas including cardiac and vascular care, neuroscience, medical and surgical procedures, and diabetes management.

The company's portfolio includes pacemakers, implantable cardioverter-defibrillators, cardiac ablation systems, stents and other cardiovascular products; neuromodulation systems, deep-brain stimulation devices and spinal technologies; surgical instruments, robotic-assisted surgery systems and gastrointestinal diagnostic tools; and insulin pumps and related diabetes technologies.

Medtronic traces its origins to 1949, when Earl Bakken and Palmer Hermundslie founded the company in Minneapolis, Minnesota.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.